https://www.remedypharmaceuticals.com/news/ 2024-09-06T15:51:35+00:00 https://www.remedypharmaceuticals.com/remedy-pharmaceuticals-secures-key-u-s-patent-allowance-for-cirara-in-treating-large-hemispheric-infarction-including-wake-up-strokes/ 2025-03-18T12:59:00+00:00 https://www.remedypharmaceuticals.com/international-stroke-conference-2025-remedy-pharmaceuticals-unveils-landmark-cirara-data-demonstrating-significant-improvements-in-stroke-outcomes/ 2025-02-19T00:27:58+00:00 https://www.remedypharmaceuticals.com/remedy-pharmaceuticals-to-showcase-groundbreaking-phase-3-charm-study-data-on-cirara-at-international-stroke-conference-2025/ 2025-01-29T13:59:00+00:00 https://www.remedypharmaceuticals.com/remedy-pharmaceuticals-receives-fda-guidance-to-advance-cirara-for-treatment-of-severe-stroke/ 2024-11-19T13:59:00+00:00 https://www.remedypharmaceuticals.com/remedy-pharmaceuticals-announces-fda-orphan-drug-designation-granted-for-the-treatment-of-large-territory-acute-ischemic-stroke-with-cirara/ 2024-10-22T12:59:00+00:00 https://www.remedypharmaceuticals.com/remedy-pharmaceuticals-phase-3-trial-in-large-lesion-stroke-patients-demonstrates-statistically-significant-effect-at-one-year/ 2024-10-01T12:59:00+00:00 https://www.remedypharmaceuticals.com/remedy-pharmaceuticals-announces-further-analyses-from-phase-3-study-reveals-cirara-could-significantly-improve-independent-ambulation-in-large-hemispheric-infarction-patients/ 2024-09-06T15:44:21+00:00 https://www.remedypharmaceuticals.com/remedy-pharmaceuticals-gets-rights-to-acute-stroke-drug-back-from-biogen-announces-clinically-meaningful-and-statistically-significant-results-from-pre-specified-subgroup-and-post-hoc-analyses-of-pha/ 2024-05-29T12:01:00+00:00